Recursion Pharmaceuticals, Inc. - Class A (RXRX) Covered Calls

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that integrates artificial intelligence, automation, and high-throughput biology to industrialize drug discovery. Its proprietary Recursion OS platform utilizes machine learning to analyze massive biological and chemical datasets to identify novel relationships and accelerate development. The company maintains a pipeline across multiple areas including oncology, rare diseases, and infectious diseases.

You can sell covered calls on Recursion Pharmaceuticals, Inc. - Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RXRX (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Recursion Pharmaceuticals, Inc. (RXRX) operates as a "TechBio" company that seeks to redefine drug discovery by combining experimental biology and automation with advanced computational tools. The foundation of its business is the Recursion Operating System (OS), which integrates a massive wet-lab infrastructure with a custom supercomputer. This system generates and analyzes proprietary biological and chemical datasets to map trillions of searchable relationships, allowing the company to identify potential treatments without being limited by existing human bias or traditional hypotheses.

The company pipeline includes several clinical-stage candidates targeting significant unmet medical needs. Key programs include REC-4881 for familial adenomatous polyposis, REC-994 for cerebral cavernous malformation, and REC-2282 for neurofibromatosis type 2. Recursion also utilizes its platform to support high-value collaborations with major pharmaceutical entities. These partnerships involve utilizing its data-driven insights to identify novel targets in areas such as oncology and neuroscience, providing the company with a mix of milestone-based and royalty-linked revenue potential.

Competitive Landscape

Recursion operates at the intersection of technology and biotechnology, facing competition from both traditional drug developers and emerging AI-focused firms. Its primary competitor in the "AI-driven discovery" space is Schrodinger. While Exscientia also leverages computational modeling to streamline the R&D process, Recursion maintains a larger automated physical infrastructure. Additionally, the company competes for capital and talent with clinical-stage biotechs like Twist Bioscience and Ginkgo Bioworks.

The company also faces indirect competition from massive pharmaceutical companies that are increasingly building their own internal AI and supercomputing capabilities. This includes giants like Eli Lilly and Pfizer, who possess extensive clinical data to train their models. Recursion differentiates itself by controlling the entire data loop, from its automated "wet labs" in Salt Lake City to its proprietary high-performance computing clusters, creating a unique dataset that is not available to those relying on public research or secondary sources.

Strategic Outlook and Innovation

Recursion is focused on maturing its internal pipeline while expanding its digital chemistry capabilities. A major strategic pillar involves the integration of generative AI to predict how small molecules will interact with complex biological systems. By leveraging its supercomputer, one of the most powerful in the world, the company aims to move beyond simple screening into the predictive design of new chemical entities. This approach is intended to significantly reduce the time and cost associated with traditional preclinical research.

The company is also prioritizing its partnership with NVIDIA to develop foundation models for biology. This collaboration focuses on industrializing the process of decoding cell images and genetic perturbations at a scale previously impossible. By shifting drug discovery from a bespoke, artisan process to a scalable digital search, Recursion intends to increase the probability of clinical success. As the company moves its lead assets toward registrational studies, its strategy remains centered on proving that its platform can consistently deliver high-quality therapeutic candidates across diverse disease states.

Want more examples? RXO Covered Calls | RXT Covered Calls